176 related articles for article (PubMed ID: 36710498)
21. Risk of ocular manifestations in patients with giant cell arteritis: a nationwide study in Sweden.
Ji J; Dimitrijevic I; Sundquist J; Sundquist K; Zöller B
Scand J Rheumatol; 2017 Nov; 46(6):484-489. PubMed ID: 28276953
[TBL] [Abstract][Full Text] [Related]
22. Presentation characteristics and clinical outcome of patients with giant cell arteritis followed by a single center.
Öztaş M; Özgül H; Seyahi E; Uğurlu S
Turk J Med Sci; 2022 Aug; 52(4):917-925. PubMed ID: 36326373
[TBL] [Abstract][Full Text] [Related]
23. Incidence and Prevalence of Polymyalgia Rheumatica and Giant Cell Arteritis in a Healthcare Management Organization in Buenos Aires, Argentina.
Martínez Perez JM; Mollerach FB; Scaglioni V; Vergara F; Gandino IJ; Catoggio LJ; Rosa JE; Soriano ER; Scolnik M
J Rheumatol; 2023 Jan; 50(1):93-97. PubMed ID: 36243415
[TBL] [Abstract][Full Text] [Related]
24. Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica?
Anumolu N; Henry K; Sattui SE; Putman M
Semin Arthritis Rheum; 2023 Feb; 58():152154. PubMed ID: 36563422
[TBL] [Abstract][Full Text] [Related]
25. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
[TBL] [Abstract][Full Text] [Related]
26. Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: Clinical features and epidemiological data.
Pamuk ON; Dönmez S; Karahan B; Pamuk GE; Cakir N
Clin Exp Rheumatol; 2009; 27(5):830-3. PubMed ID: 19917168
[TBL] [Abstract][Full Text] [Related]
27. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications.
Bengtsson BA; Malmvall BE
Arthritis Rheum; 1981 Jul; 24(7):899-904. PubMed ID: 7259802
[TBL] [Abstract][Full Text] [Related]
28. Risk of venous and arterial thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica: A Veterans Health Administration population-based study in the United States.
Michailidou D; Zhang T; Stamatis P; Ng B
J Intern Med; 2022 May; 291(5):665-675. PubMed ID: 34982490
[TBL] [Abstract][Full Text] [Related]
29. Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica.
Muratore F; Pazzola G; Pipitone N; Boiardi L; Salvarani C
Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S106-11. PubMed ID: 24854380
[TBL] [Abstract][Full Text] [Related]
30. Primary Care Vasculitis: Polymyalgia Rheumatica and Giant Cell Arteritis.
Pioro MH
Prim Care; 2018 Jun; 45(2):305-323. PubMed ID: 29759126
[TBL] [Abstract][Full Text] [Related]
31. [Polymyalgia rheumatica and giant cell arteritis: recent data and current situation].
Announ N; Guerne PA
Rev Med Suisse; 2008 Mar; 4(149):696-8, 701. PubMed ID: 18472729
[TBL] [Abstract][Full Text] [Related]
32. Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica.
El Chami S; Springer JM
Rheum Dis Clin North Am; 2022 May; 48(2):493-506. PubMed ID: 35400374
[TBL] [Abstract][Full Text] [Related]
33. A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis.
Chakravarty K; Pountain G; Merry P; Byron M; Hazleman B; Scott DG
J Rheumatol; 1995 Sep; 22(9):1694-7. PubMed ID: 8523347
[TBL] [Abstract][Full Text] [Related]
34. Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort.
Esen I; Arends S; Dalsgaard Nielsen B; Therkildsen P; Hansen I; van 't Ende A; Heeringa P; Boots A; Hauge E; Brouwer E; van Sleen Y
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36631159
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.
Unizony S; McCulley TJ; Spiera R; Pei J; Sidiropoulos PN; Best JH; Birchwood C; Pavlov A; Stone JH
Arthritis Res Ther; 2021 Jan; 23(1):8. PubMed ID: 33407817
[TBL] [Abstract][Full Text] [Related]
36. [Polymyalgia rheumatica and temporal arteritis].
Vos PA; Bijlsma JW; Derksen RH
Ned Tijdschr Geneeskd; 2005 Aug; 149(35):1932-7. PubMed ID: 16159030
[TBL] [Abstract][Full Text] [Related]
37. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.
Dejaco C; Duftner C; Buttgereit F; Matteson EL; Dasgupta B
Rheumatology (Oxford); 2017 Apr; 56(4):506-515. PubMed ID: 27481272
[TBL] [Abstract][Full Text] [Related]
38. Differences in clinical manifestations and prognosis of Chinese giant cell arteritis patients with or without polymyalgia rheumatica.
Zhang Y; Wang D; Chu X; Zhang W; Zeng X
Ir J Med Sci; 2019 May; 188(2):713-720. PubMed ID: 30251177
[TBL] [Abstract][Full Text] [Related]
39. Lower extremity vasculitis in polymyalgia rheumatica and giant cell arteritis.
Kermani TA; Warrington KJ
Curr Opin Rheumatol; 2011 Jan; 23(1):38-42. PubMed ID: 21037479
[TBL] [Abstract][Full Text] [Related]
40. Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data.
Hemmig AK; Gozzoli D; Werlen L; Ewald H; Aschwanden M; Blockmans D; Brouwer E; Buchanan RRC; Camellino D; Campochiaro C; Cimmino MA; Corominas H; Gloy V; Henckaerts L; Kyburz D; Moya-Alvarado P; Owen CE; Stegert M; Tomelleri A; van Sleen Y; Yamashita H; Imfeld S; Berger CT; Hemkens LG; Daikeler T
Semin Arthritis Rheum; 2022 Aug; 55():152017. PubMed ID: 35537222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
